

Product Name: InVivoMAb Anti-Nipah virus/NiV Fusion glycoprotein/F Trimer Antibody (Fab92) (VK521070)

Catalog #: AMRe60128

For research use only.

Summary

Description	Recombinant human monoclonal antibody
Host	Human
Application	ELISA, Neutralization
Reactivity	Nipah virus (NiV)
Conjugation	Unconjugated
Modification	Unmodified
Isotype	IgG1
Clonality	Monoclonal
Form	Liquid
Concentration	
Storage	Aliquot and store at -20°C (valid for 12 months). Avoid freeze/thaw cycles.
Shipping	Ice bags
Buffer	0.01M PBS, pH 7.4.
Purification	Protein A/G purified from cell culture supernatant.

Application

Dilution Ratio ELISA 1:5000-1:20000

Molecular Weight

Antigen Information

Gene Name	Fusion glycoprotein F0
Alternative Names	Fusion glycoprotein F0, Protein F, Fusion glycoprotein F2, Fusion glycoprotein F1, F
Gene ID	
SwissProt ID	Q9IH63
Immunogen	

Background

Nipah virus (NiV), a highly pathogenic zoonotic paramyxovirus, mediates host cell entry through the coordinated action of two envelope glycoproteins: the attachment glycoprotein (G), which engages the host cell receptors ephrin-B2 and ephrin-B3, and

the fusion glycoprotein (F), which drives membrane fusion following receptor binding. These viral surface proteins, along with the viral RNA-dependent RNA polymerase (RdRp) complex comprising the nucleoprotein (N), phosphoprotein (P), and large polymerase protein (L), constitute the primary molecular targets for therapeutic intervention and vaccine development. The conserved receptor-binding interface of the G protein and the fusion machinery of the F protein represent particularly attractive targets for neutralizing antibodies and entry inhibitors, while the viral replication machinery offers potential targets for broad-spectrum antiviral compounds targeting paramyxovirus transcription and replication.

Research Area

Microbiology&Infectious Disease